| Anjali Subbaswamy, | |
|
Pediatric Intensive Care Unit, Unm Hospitals, Albuquerque, NM 87131-0001 | |
| (505) 272-2111 | |
| Not Available |
| Full Name | Anjali Subbaswamy |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Critical Care Medicine |
| Location | Pediatric Intensive Care Unit, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528154655 | NPI | - | NPPES |
| Entity Name | Unm Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831218627 PECOS PAC ID: 4981795267 Enrollment ID: O20070801000589 |
News Archive
New guidance has been released today by the National Institute for Health and Care Excellence (NICE) recommending Olympus Medical's transurethral resection in saline (TURis) system for use in surgery to reduce the size of enlarged prostate glands in men. NICE published the guidance in light of the potential it offers NHS hospitals to realise substantial cost savings of £285-£375 per patient whilst also improving patient outcomes.
As many as half of all women and a quarter of men over the age of 50 can expect to sustain a fractured bone related to osteoporosis or low bone density. To enhance prevention and treatment of these fragility fractures, NewYork-Presbyterian Hospital/Columbia University Medical Center has implemented an innovative program called Own the Bone™ developed by the American Orthopaedic Association.
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy agents.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anjali Subbaswamy, 933 Bradbury Dr Se, Albuquerque, NM 87106-4374 Ph: (505) 272-3120 | Anjali Subbaswamy, Pediatric Intensive Care Unit, Unm Hospitals, Albuquerque, NM 87131-0001 Ph: (505) 272-2111 |
News Archive
New guidance has been released today by the National Institute for Health and Care Excellence (NICE) recommending Olympus Medical's transurethral resection in saline (TURis) system for use in surgery to reduce the size of enlarged prostate glands in men. NICE published the guidance in light of the potential it offers NHS hospitals to realise substantial cost savings of £285-£375 per patient whilst also improving patient outcomes.
As many as half of all women and a quarter of men over the age of 50 can expect to sustain a fractured bone related to osteoporosis or low bone density. To enhance prevention and treatment of these fragility fractures, NewYork-Presbyterian Hospital/Columbia University Medical Center has implemented an innovative program called Own the Bone™ developed by the American Orthopaedic Association.
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy agents.
› Verified 9 days ago
Janell Fuller, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3rd Ambulatory Care Ctr, 2211 Lomas Blvd. Ne, Albuquerque, NM 87131 Phone: 505-272-2345 | |
Ivana Radovanovic, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2211 Lomas Ne Acc 3w, Albuquerque, NM 87131 Phone: 505-272-6632 Fax: 505-272-6620 | |
Lynn Longfield, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4420 Irving Blvd Nw, Albuquerque, NM 87114 Phone: 505-823-1010 Fax: 505-797-4503 | |
Thomas Rothfeld, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 401 San Mateo Blvd Se, Pmg San Mateo, Albuquerque, NM 87108 Phone: 505-462-7306 Fax: 505-462-7495 | |
Dr. Leslie Erin Strickler, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 2211 Lomas Blvd Ne, Albuquerque, NM 87106 Phone: 505-272-5551 Fax: 505-272-6845 | |
Jennifer M Garcia, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2001 El Centro Familiar Blvd Sw, Albuquerque, NM 87105 Phone: 505-873-7400 Fax: 505-224-8797 | |
Dr. William B Hawk, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5904 Holly Ave Ne, Albuquerque, NM 87113 Phone: 505-298-2505 Fax: 505-298-2985 |